Myriad (MYGN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Core Insights - Myriad Genetics reported $195.9 million in revenue for the quarter ended March 2025, reflecting a year-over-year decline of 3.1% and an EPS of -$ 0.03 compared to - $0.01 a year ago [1] - The revenue fell short of the Zacks Consensus Estimate of$ 199.96 million by 2.03%, while the EPS exceeded the consensus estimate of - $0.05 by 40% [1] Revenue Performance by Product - Prenatal revenue reached$ 49.30 million, surpassing the estimated $44.69 million, marking a year-over-year increase of 59.6% [4] - Hereditary Cancer revenue was$ 86.30 million, below the average estimate of $92.46 million, representing a year-over-year decline of 2% [4] - Pharmacogenomics revenue totaled$ 31 million, slightly below the estimated $32.46 million, with a year-over-year decrease of 20.3% [4] - Tumor Profiling revenue was$ 29.30 million, compared to the average estimate of $30.66 million, indicating a year-over-year decline of 5.2% [4] Stock Performance - Myriad's shares have returned -4.6% over the past month, contrasting with the Zacks S&P 500 composite's increase of 11.5% [3] - The stock currently holds a Zacks Rank 2 (Buy), suggesting potential outperformance against the broader market in the near term [3]